Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Payables (2019 - 2025)

Pulmonx has reported Payables over the past 7 years, most recently at $4.0 million for Q4 2025.

  • Quarterly Payables fell 42.72% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 42.72% year-over-year, with the annual reading at $4.0 million for FY2025, 42.72% down from the prior year.
  • Payables was $4.0 million for Q4 2025 at Pulmonx, down from $6.5 million in the prior quarter.
  • Over five years, Payables peaked at $18.9 million in Q4 2021 and troughed at $1.8 million in Q4 2022.
  • The 5-year median for Payables is $6.0 million (2022), against an average of $7.8 million.
  • Year-over-year, Payables plummeted 90.23% in 2022 and then skyrocketed 180.31% in 2024.
  • A 5-year view of Payables shows it stood at $18.9 million in 2021, then plummeted by 90.23% to $1.8 million in 2022, then surged by 97.62% to $3.7 million in 2023, then soared by 91.76% to $7.0 million in 2024, then plummeted by 42.72% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Payables are $4.0 million (Q4 2025), $6.5 million (Q3 2025), and $6.7 million (Q2 2025).